Combination vaccines

Journal of Global Infectious Diseases

Volumn 3, Issue 1, 2011, Pages 63-72

  Skibinski, David A G ^a   Baudner, Barbara C ^a   Singh, Manmohan ^b   O'hagan, Derek T ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Novartis Vaccines Cambridge   (United States)

Author keywords

Adjuvant; Combination vaccine; Diphtheria; Haemophilus influenza; Hepatitis B; Neisseria meningitidis; Pertussis; Poliovirus; Streptococcus pneumoniae; Tetanus

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; KINRIX; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; CHILD; CHILD HEALTH; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MEASLES; MENINGOCOCCOSIS; MONOTHERAPY; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RUBELLA; TETANUS; TREATMENT INDICATION;

EID: 79952979544     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.77298     Document Type: Conference Paper

References (73)

1. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin SA, Orenstein WA, Offitt P, editors. Vaccines. 5 th ed. USA: Saunders, PA; 2008. p. 471-528.
2. Centers for Disease Control and Prevention-United States. Recommended Immunization Schedule for Persons Aged 0 Through 6 Years. 2010.
3. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007;26:496-500. (Pubitemid 46847310)
4. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006;25:507-12. (Pubitemid 43863360)
5. Weston WM, Klein NP. Kinrix: A new combination DTaPIPV vaccine for children aged 46 years. Expert Rev Vaccines 2008;7:1309-20.
6. Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPaHBVIPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009;8:663-78.
7. Bogaerts H. The future of childhood immunizations: Examining the European experience. Am J Manag Care 2003;9:S30-6. (Pubitemid 36187462)
8. White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaPIPV/Hib vaccine. Expert Rev Vaccines 2009;8:831-40.
9. Schmitt HJ. Immunogenicity and reactogenicity of two Haemophilus influenzae type b tetanus conjugate vaccines administered by reconstituting with diphtheria-tetanus-acellular pertussis vaccine or given as separate injections. In 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA; 1995.
10. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 1999;354:2063-8.
11. Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001;184:1617-20. (Pubitemid 33139751)
12. Schmitt HJ, Knuf M, Ortiz E, Snger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000;137:304-12.
13. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20:S10-8. (Pubitemid 33055095)
14. Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: Impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 2008;7:97-115. (Pubitemid 351357968)
15. Decker MD, Edwards KM, Bogaerts HH. Combination vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5 th ed. USA: Saunders, PA; 2008. p. 1069-101.
16. Mawas F, Dickinson R, Douglas-Bardsley A, Xing DK, Sesardic D, Corbel MJ. Immune interaction between components of acellular pertussis-diphtheria-tetanus (DTaP) vaccine and Haemophilus influenzae b (Hib) conjugate vaccine in a rat model. Vaccine 2006;24:3505-12.
17. Schutze MP, Deriaud E, Przewlocki G, LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989;142:2635-40. (Pubitemid 19114875)
18. McGuirk P, Johnson PA, Ryan EJ, Mills KH. Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens. J Infect Dis 2000;182:1286-8.
19. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003;188:481-5. (Pubitemid 37011798)
20. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005;10:E050929.2.
21. Steinhoff M, Goldblatt D. Conjugate HIB vaccines. Lancet 2003;361:360-1. (Pubitemid 36164964)
22. Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007;26:31-5. (Pubitemid 46045748)
23. Mast E, Mahony F, Kane M, Margolis H. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5 th ed. USA: Saunders, PA; 2008. p. 205-241.
24. Greenberg DP, Wong VK, Partridge S, Chang SJ, Jing J, Howe BJ, et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 2000;19:1135-40. (Pubitemid 32003355)
25. Greenberg DP, Wong VK, Partridge S, Howe BJ, Ward JI. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. Pediatr Infect Dis J 2002;21:769-77.
26. Pichichero ME, Blatter MM, Reisinger KS, Harrison CJ, Johnson CE, Steinhoff MC, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002;21:854-9.
27. European Agency for the Evaluation of Medicinal Products (EMEA). European Medicines Agency recommends suspension of Hexavac. 2005. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Hexavac/29736905en.pdf [last accessed on 2010 Jan].
28. Zanetti AR, Mariano A, Roman L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: An Italian multicentre study. Lancet 2005;366:1379-84. (Pubitemid 41443405)
29. Da Villa G, Roman L, Sepe A, Iorio R, Paribello N, Zappa A, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007;25:3133-6. (Pubitemid 46482751)
30. Centers for Disease Control and Prevention-CDC. Pertussis vaccination: Acellular pertussis vaccine for reinforcing and booster use-supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). 1992. Morbidity Mortality Weekly Report (MMWR) Recomm. Rep. 41(RR-1), 1-10.
31. Cohen R, Schuerman L. Reactogenicity of a new DTPa-HBV-IPV (+ and/Hib) vaccines after primary and booster doses. Presented at: 18 th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands, 2000.
32. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000;106:E51.
33. Deloria MA, Blackwelder WC, Decker MD, Englund JA, Steinhoff MC, Pichichero ME, et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995;96:592.
34. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus- diphtheria vaccines. Pediatrics 2000;105:e12.
35. Schmitt HJ, Beutel K, Schuind A, Knuf M, Wagner S, Mschenborn S, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997;130:616-23. (Pubitemid 27492654)
36. Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 2001;19:4720-6. (Pubitemid 32800756)
37. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Seminars in Pediatric Infectious Diseases 2003;14:196-8. (Pubitemid 36994971)
38. Rowe J, Yerkovich ST, Richmond P, Suriyaarachchi D, Fisher E, Feddema L, et al. Th2-associated local reactions to the acellular diphtheria-tetanus- pertussis vaccine in 4-to 6-year-old children. Infect Immun 2005;73:8130-5. (Pubitemid 41740300)
39. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 2005;23:3829-35. (Pubitemid 40704747)
40. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2005;24:70-7. (Pubitemid 40353319)
41. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:1-8.
42. Herz A, Black S, Shinefield H, Noriega F, Greenberg D. Safety of Combined DTaP-IPV + PRP-T (Pentacel) administered at 2, 4, 6, and 15 to 18 months of age. Pediatric Academic Societies Annual Meeting. Washington, DC, USA. 2005 May 14-17.
43. Huang LM, Chang LY, Tang H, Bock HL, Lu CY, Huang FY, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health 2005;37:517.
44. Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003;21:4194-200. (Pubitemid 37130264)
45. Snger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007;166:1229-36. (Pubitemid 350029473)
46. NHS Routine childhood immunization programme January 2008. Available from: http://www.immunisation.nhs.uk/immunisation-schedule [last accessed on 2010 Jan].
47. Robert Koch-Institut. Recommendation of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute for pertussis vaccination. Epidemiologisches Bulletin 2006;3:21-3.
48. Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP. IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 2006;24:2057-64. (Pubitemid 43255147)
49. Noriega F, Tsang P, Jemiolo D, Voloshen T, Greenberg DP. The Pentacel Investigators Study Group. Immunogenicity of a four dose series of DTaP-IPV//PRP-T (Pentacel). The 5 th Pediatric Infectious Disease Conference. Napa, CA, USA. Oct 2005
50. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
51. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006;24:4727-36. (Pubitemid 43776787)
52. Tozzi AE, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giudice ML. Can hexavalent vaccines be simultaneously administered with pneumococcal or meningococcal conjugate vaccines? Hum Vaccin 2007;3:252-9.
53. Tejedor JC, Omeaca F, Garca-Sicilia J, Verdaguer J, Van Esso D, Esporrn C, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004;23:1109-15. (Pubitemid 40812757)
54. Schmitt HJ, Habermehl P, Knuf M, Ypma E, Borkowski A. Safety reactogenicity and mmunogenicity/priming following 2 vs. 3 doses of a meningococcal C conjugate vaccine (MCC) given concomitantly with DTaP-IPV-HBV/Hib vaccine to infants in 23 rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain, 18-20 May 2005.
55. Schmitt HJ, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, et al. Immunogenicity, reactogenicity and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 2007;14:426-34. (Pubitemid 46732554)
56. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gmez-Campder JA, Navarro ML, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006;25:713-20. (Pubitemid 44162129)
57. Halperin SA, McDonald J, Samson L, Danzig L, Santos G, Izu A, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: A randomized double-blind study. Clin Invest Med 2002;25:243-51. (Pubitemid 36204019)
58. Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull P, et al. Immunogenicity and safety of MenACWY-CRM, A novel quadrivalent meningococcal conjugate vaccine, administered concomitantly with Tdap in healthy subjects 11-25 years of age. Presented at: 26 th Annual Meeting of the European Society for Paediatric Infectious Diseases. Graz, Austria, 2008.
59. Dagan R, Goldblatt D, Maleckar JR, Yach M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004;72:5383-91. (Pubitemid 39223427)
60. Baraldo K, Mori E, Bartoloni A, Petracca R, Giannozzi A, Norelli F, et al. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect Immun 2004;72:4884-7. (Pubitemid 38989352)
61. Baraldo K, Mori E, Bartoloni A, Norelli F, Grandi G, Rappuoli R, et al. Combined conjugate vaccines: Enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect Immun 2005;73:5835-41. (Pubitemid 41193020)
62. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-'The long and winding road'. Drug Discov Today 2009;14:541-51.
63. Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 2006;24:1680-6. (Pubitemid 43238245)
64. Coombes L, Stickings P, Tierney R, Rigsby P, Sesardic D. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. J Immunol Methods 2009;350:142-9.
65. Cuervo ML, Sterling AL, Nicot IA, Rodrguez MG, Garca OR. Validation of a new alternative for determining in vitro potency in vaccines containing Hepatitis B from two different manufacturers. Biologicals 2008;36:375-82. (Pubitemid 50234320)
66. Giffroy D, Mazy C, Duchne M. Validation of a new ELISA method for in vitro potency assay of hepatitis B-containing vaccines. Pharmeuropa Bio 2006;2006:7-14.
67. Prieur S, Broc S, Gal M, Poirier B, Fuchs F. Development of an in vitro potency test for tetanus vaccines. In: Brown F, Hendriksen C, Sesardic D, Cussler K, editors. Advancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccines and Hormones. Basel: S. Karger AG Publiation; 2002. p. 37.
68. Xing DK, McLellan K, Corbel MJ, Sesardic D. Estimation of antigenic tetanus toxoid extracted from biodegradable microspheres. Biologicals 1996;24:57-65. (Pubitemid 26148443)
69. Bolgiano B, Fowler S, Turner K, Sesardic D, Xing DK, Crane DT, et al. Monitoring of diphtheria, pertussis and tetanus toxoid by circular dichroism, fluorescence spectroscopy and size-exclusion chromatography. In: Brown F, Corbel MJ, Griffiths E, editors. Physico-chemical Procedures for the Characterization of Vaccines, S. Karger AG, Basel: 2000. p. 51.
70. Leenaars PP, Kersten GF, de Bruijn ML, Hendriksen CF. An in vitro approach in quality control of toxoid vaccines. Vaccine 2001;19:2729-33. (Pubitemid 32234296)
71. Metz B, Jiskoot W, Hennink WE, Crommelin DJ, Kersten GF. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine 2003;22:156-67. (Pubitemid 37412260)
72. Metz B, Jiskoot W, Mekkes D, Kingma R, Hennink WE, Crommelin DJ, et al. Quality control of routine, experimental and real-time aged diphtheria toxoids by in vitro analytical techniques. Vaccine 2007;25:6863-71. (Pubitemid 47391108)
73. Zhu D, Huang S, Gebregeorgis E, McClellan H, Dai W, Miller L, et al. Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA). J Immunol Methods 2009;344:73-8.